SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors express significant frustration and skepticism toward the Board's decision to accept an all-cash acquisition offer, which many feel drastically undervalues the company's cash position, core drug assets, and future growth potential. The community is actively debating the merits of the deal, with some shareholders organizing to oppose the tender offer and others seeking legal avenues to challenge what they characterize as an unethical 'fire sale' by management.

MMTec, Inc. engages in the holding of an equity interest in MM Future. It operates through the Gujia, MM Future and HC Securities and MM Global. The Gujia, MM Future and HC Securities segment provide market data services and consulting services. The MM Global segment is involved in introducing a broker that clears all transactions through a clearing broker dealer and earns commission income, placement agent services fee, and other related income from customers. The company was founded on January 4, 2018 and is headquartered in Hong Kong.

Mmtec Inc

Mmtec Inc is generating significant market interest as traders speculate on potential short squeeze dynamics and the company's efforts to maintain its NASDAQ listing status. Community discussions are heavily focused on the stock's extreme volatility and its tendency to mirror past microcap momentum plays, with participants actively debating the risks of delisting against the possibility of aggressive rallies.

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YDES is currently garnering significant attention from retail traders due to its status as a recent Nasdaq uplisting with a remarkably low float, leading to discussions about potential volatility and short-squeeze setups. The community is closely monitoring the stock's price action alongside its associated warrants, debating whether current valuations present a mispricing opportunity or a speculative trap.

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LENSAR Inc

LENSAR Inc. shares are under significant pressure following the mutual termination of its merger agreement with Alcon, a decision prompted by mounting regulatory opposition from the FTC. The community is actively debating the company's standalone future, weighing concerns over operational liquidity and intense market competition against the potential durability of its recurring revenue model and ALLY system adoption.

Ethereum Classic

Ethereum Classic is experiencing renewed community focus as investors speculate on a long-awaited breakout, with many sentiment-driven discussions highlighting the contrast between the token's historical performance and its current suppressed price action. Traders are actively debating the timing of a potential trend reversal, frequently citing broader crypto market catalysts and comparing its utility to other established proof-of-work assets.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics is seeing intense retail interest as investors focus on its role as a specialized supplier for U.S. defense programs and high-growth AI infrastructure. The community is actively debating the stock's low float and strong insider ownership, with many monitoring for potential momentum breakouts tied to ongoing government contract announcements.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is experiencing significant momentum and investor interest following its listing on major brokerage platforms and the launch of new institutional-grade DeFi features. Community members are actively debating its potential as a primary competitor to traditional exchanges, with many focusing on its deep liquidity, high-volume perpetual trading, and aggressive token buyback programs as key drivers for long-term growth.

Maulcoin

Maulcoin is trending as the community celebrates the restoration of its ticker symbol and anticipates the upcoming release of a price chart. Supporters are actively engaging in community-led growth strategies, framing the project as an honest, long-term alternative to typical pump-and-dump meme coins.

WorldFinancial

WLFI is currently facing significant volatility and intense community debate as investors react to congressional scrutiny regarding the project's foreign investment ties and its relationship with the Trump administration. While some participants view the current price action as a strategic accumulation opportunity ahead of upcoming industry forums, others express concern over token dilution, governance transparency, and the potential for the project to follow the downward trajectory of past politically-linked assets.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing satirical project that has transitioned onto the Solana network, with the community positioning it as a cultural successor to early Bitcoin lore. Supporters are actively discussing its 15-year history and perceived potential for generational wealth, while debates continue between those dismissing it as a meme-driven joke and those convinced it represents a unique opportunity in the current market cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tevogen CEO Ryan Saadi said in a letter to shareholders on Friday that the company is “actively evaluating” potential acquisitions to drive value.“If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time,” the CEO said.As <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/06/3251264/0/en/Letter-to-Shareholders-from-CEO-Dr-Ryan-Saadi.html">per</a> the CEO, the combined entities under consideration for acquisition may generate aggregate annual revenues in excess of $50 million, based on preliminary evaluations.<h2 class="st-heading-2">Proposed Deals</h2>The CEO’s letter comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.If the deal with Apozel goes through, it could provide Tevogen with an established generics platform, the company had said. This includes 11 FDA-approved generic products for the U.S. market and others awaiting approval by the FDA or currently under development.Tevogen is also actively considering other transactions, the company said earlier this week, while expressing its interest in domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers.Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization.Earlier this week, the company also said that its Board has approved a reverse stock split of its common stock at a ratio of 50 for 1 to regain compliance with Nasdaq’s $1 minimum bid price requirement. The stock began trading on a split-adjusted basis on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVGN stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/TVGN">TVGN stock</a> has erased nearly 87% of its value over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lnth-stock-up-after-hours/cZdLQ3SRI4B">Why Is LNTH Stock Up After Hours?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions 

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.

Equity

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.


Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month Low - Here's What Happened

Tevogen Bio (NASDAQ:TVGN) Reaches New 12-Month Low - Should You Sell...

<ul class="summary-bullets"><li>The potential &nbsp;transaction will be subject to multiple factors including the completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions, the company said.</li><li>While there is no guarantee that any transaction will materialize, Tevogen is also actively considering other transactions, the company said.&nbsp;</li><li>Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization. &nbsp;</li></ul>Shares of Tevogen (TVGN) closed 17% lower on Thursday after the company said that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.If the deal goes through, it could provide Tevogen with an established generics platform, the company said. This includes 11 FDA-approved generic products for the U.S. market and others awaiting approval by the FDA or currently under development.Shares of the company edged up 6% after hours.<h2 class="st-heading-2">Details Of The Deal</h2>“Tevogen Generics was launched with the objective of supporting pharmaceutical affordability and domestic manufacturing in the United States. The potential acquisition of Apozeal represents a meaningful step toward that strategy,” Tevogen CEO Ryan Saadi said. &nbsp;The potential &nbsp;transaction will be subject to multiple factors including the completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions, the company said.While there is no guarantee that any transaction will materialize, Tevogen is also actively considering other transactions, the company said, while expressing its interest in domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers.Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization.Earlier this week, the company also said that its Board has approved a reverse stock split of its common stock at a ratio of 50 for 1 to regain compliance with Nasdaq’s $1 minimum bid price requirement. The stock is expected to start trading on a split-adjusted basis on March 6. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVGN stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/TVGN">TVGN stock</a> has erased nearly all of its value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tnya-pulls-back-after-hours-following-significant-1.13b-deal-spurred-rally/cZdXexXRIEb">TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Tevogen Shares Take Further Beating On Gauging Deal With Apozel Pharmaceuticals

If the deal goes through, it could provide Tevogen with an established generics platform, the company said.

Tevogen Bio (TVGN) to Release Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Tevogen Bio (NASDAQ:TVGN) Trading 7.9% Higher - Should You Buy?

Tevogen Bio (NASDAQ:TVGN) Stock Price Up 7.9% - Should You Buy...

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's Why

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Time to Sell?

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Price Target Cut to $5.00 by Analysts at D. Boral Capital

D. Boral Capital decreased their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

Tevogen Bio (NASDAQ:TVGN - Get Free Report) posted its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter...

Buy When There’s Blood in the Streets: Why the DeepSeek Rout May Be Good News for Microsoft Stock

Microsoft’s stock presents a buying opportunity due to its strong financials, strategic partnerships, and potential to benefit from cheaper AI models in the long run.

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Current Price	$5.73
Prev Close	$5.86
Open	$5.80
Dividend Yield	0.00%
50-Day Moving Average	$9.46
Beta	0.99
Avg. Volume	51,403.99
PE Ratio	-0.77

52-Week High	$75.50
52-Week Low	$4.14
Market Capitalization	$24.4M
EPS (Annual)	-$8.08
Price to Book	-1.35
Revenue Per Employee	$0.00

TVGN
Tevogen Bio Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TVGN News

TVGNTevogen Bio Holdings Inc.